No recurrence of the tumor was found for 3 years postoperatively.<h4>Conclusion</h4>The case supports the strategy of neoadjuvant ALK inhibitors for N3 unresectable locally advanced lung cancer, expanding the spectrum of treatment of stage IIIB-N3 lung cancer. This evidence concerns the gene ALK and lung carcinoma.